Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379260 | 0.90 | NPC1 (0.38) | POLBNPC1MEN1KMT2ATSHR | |
| SCHEMBL19117841 | 0.78 | POLB (0.34) | POLBNPC1TSHRL3MBTL1ACHE | |
| SCHEMBL456197 | 0.77 | MEN1 (0.48) | MEN1KMT2ATSHRL3MBTL1CYP1A2 | |
| SCHEMBL12755486 | 0.76 | NPC1 (0.37) | POLBNPC1TSHRL3MBTL1ACHE | |
| SCHEMBL6972555 | 0.76 | NPC1 (0.37) | POLBNPC1TSHRL3MBTL1ACHE | |
| SCHEMBL6458952 | 0.75 | CYP4F2 (0.37) | MEN1KMT2ATSHRL3MBTL1CYP1A2 | |
| SCHEMBL30440649 | 0.75 | MEN1 (0.47) | MEN1KMT2ATSHRL3MBTL1CYP1A2 | |
| SCHEMBL27889242 | 0.75 | MEN1 (0.47) | MEN1KMT2ATSHRL3MBTL1CYP1A2 | |
| SCHEMBL8306724 | 0.75 | MEN1 (0.47) | POLBMEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL19105275 | 0.74 | ACHE (0.36) | POLBNPC1TSHRL3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-12-28 | — | — | US | disclosed |
| US-9777012-B2 | Substituted furo[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-10-03 | — | — | US | disclosed |
| WO-2016100495-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176891-A1 | Conformationally Restricted 4-Substituted-2,6-dimethylfuro[2,3-d]pyrimidines as Multi-targeted Receptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents | ERBB2, MAP2, TUBB6 | POLB 1842/4885NPC1 2637/4885MEN1 3516/4885 |
| US-20170369500-A1 | CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTI-TUMOR AGENTS | ERBB2, DCK, DHFR | POLB 981/4885NPC1 4128/4885MEN1 3731/4885 |
| US-10189853-B2 | Conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as anti-tumor agents | ERBB2, DCK, DHFR | POLB 981/4885NPC1 4128/4885MEN1 3731/4885 |
| US-20200290976-A1 | RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF | TUBB3, MAP2, MAPT | POLB 1224/4885NPC1 446/4885MEN1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.